

---

# Dipyridamole, Cold Pressor Test, and Demonstration of Endothelial Dysfunction: A PET Study of Myocardial Perfusion in Diabetes

Andreas Kjaer, MD, PhD, DMS<sup>1</sup>; Christian Meyer, MD, PhD<sup>1</sup>; Flemming S. Nielsen, MD, DMS<sup>2</sup>; Hans-Henrik Parving, MD, DMS<sup>2</sup>; and Birger Hesse, MD, DMS<sup>1</sup>

<sup>1</sup>Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; and <sup>2</sup>Steno Diabetes Center, Gentofte, Denmark

---

Much evidence suggests endothelial dysfunction to be present in non-insulin-dependent diabetes mellitus (NIDDM) and to be important for the development of myocardial ischemia. Endothelial function in the coronary vessels may be studied in various ways. We compared the effect of cold pressor testing (CPT) with that of dipyridamole, a pharmacologic vasodilator, on coronary blood flow (CBF) measured by PET in NIDDM patients and healthy volunteers. In addition, we studied the effect of acute angiotensin-converting enzyme (ACE) inhibition on the flow response. **Methods:** Ten NIDDM patients and 10 control subjects participated. Myocardial perfusion was determined at baseline, during CPT, and after dipyridamole infusion by PET using intravenous <sup>13</sup>N-ammonia. **Results:** Resting CBF was similar in NIDDM patients and in control subjects. CPT increased CBF by 20% in the control group, whereas no increase was observed in the patients. After dipyridamole infusion, CBF increased 2- to 3-fold in patients and 3- to 4-fold in control subjects. The increase and maximal CBF were significantly higher in control subjects than in patients. During ACE-inhibitor infusion, which had no influence on resting CBF in patients or control subjects ( $n = 5$ ), CPT increased CBF by 14% in the NIDDM group. After dipyridamole, CBF increased 3- to 4-fold in both groups. The increase in CBF and maximal CBF in the 2 groups were not different during ACE-inhibitor infusion. **Conclusion:** In these NIDDM patients without evidence of epicardial coronary disease, endothelial dysfunction is strongly suggested by an impaired increase in CBF both to dipyridamole and to CPT. This dysfunction was reversed by infusion of an ACE inhibitor. Although ACE inhibition during CPT did induce significant increases in CBF in the patients, the changes during ACE inhibition were small compared with the dipyridamole response, and the absence of CBF increase during CPT in 3 of the 10 control subjects further limits the value of CPT for the study of coronary endothelial dysfunction.

**Key Words:** cold pressor test; diabetes; endothelial dysfunction; myocardial perfusion; PET

**J Nucl Med 2003; 44:19–23**

---

Received Apr. 12, 2002; revision accepted Aug. 21, 2002.  
For correspondence or reprints contact: Andreas Kjaer, MD, PhD, DMS, Section 4011, Department of Clinical Physiology and Nuclear Medicine, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.  
E-mail: kjaer@mfi.ku.dk

**E**vidence of endothelial dysfunction has frequently been found in diseases such as hypertension, hypercholesterolemia, and diabetes. The clinical importance of endothelial dysfunction in the development of coronary artery disease is probably related to impaired endothelium-dependent vasodilation in both coronary conductance and coronary resistance vessels. This impairment leads to an inadequate increase in coronary blood flow (CBF) in response to increased metabolic demand causing ischemia. Endothelial dysfunction may be demonstrated as a decreased vasodilatation response to an intracoronary infusion of acetylcholine and methacholine. The endothelium-dependent vasodilatation may also be demonstrated by intracoronary administration of an NO synthesis inhibitor, for example, N<sup>G</sup>-monomethyl-L-arginine (L-NMMA), that blocks endothelium-dependent vasodilatation, for example, flow-mediated coronary artery dilatation. In patients with non-insulin-dependent diabetes mellitus (NIDDM), endothelial dysfunction has been demonstrated using acetylcholine (1,2), methacholine (3,4), and L-NMMA (2).

A correlation between changes in blood flow during intravascular acetylcholine infusion and during cold pressor testing (CPT) (5) has supported the use of CPT as a non-invasive way to study coronary endothelial function with PET. The principle of CPT is nociception-induced activation of the sympathoadrenomedullary system. This, in turn, is supposed to lead to an increased oxygen demand of the myocardium and a secondary increased CBF in the normal heart, largely because of endothelium-dependent flow-mediated vasodilation. However, in patients with endothelial dysfunction, the loss of vasodilatory mechanisms leads to an absence of or insufficient increase in CBF. Dipyridamole is used as a pharmacologic stressor to measure maximal coronary flow, which is highly dependent on the function of the endothelium. The utility of PET in combination with pharmacologic stressors to measure flow reserve has previously been described (6,7).

To establish the clinical value of CPT in the evaluation of coronary endothelial function, we studied CBF by PET in

NIDDM patients and in healthy volunteers during CPT and pharmacologic stress by dipyridamole both in a baseline situation and during angiotensin-converting enzyme (ACE) inhibition, which is known to improve endothelial dysfunction in peripheral vessels.

## MATERIALS AND METHODS

### Study Population

Ten patients with NIDDM and 10 healthy volunteers, as control subjects, were included. All patients were normoalbuminuric and normotensive, had normal cholesterol levels, and had normal results from exercise testing. They were recruited from the Steno Diabetes Center, Gentofte, Denmark, and the control group was recruited from the Naestved Population Study (Naestved, Denmark). The study was approved by the local scientific ethical committee, and all participants gave their written informed consent. Details on the study groups are shown in Table 1.

### General Protocol

Myocardial perfusion was determined by PET using intravenous  $^{13}\text{N}$ -ammonia as a tracer. For each subject, serial PET images were acquired at rest (baseline), during CPT, and after pharmacologic stress using dipyridamole. The whole series was performed twice: once during placebo infusion and once during infusion of the ACE inhibitor perindoprilat. The 2 studies were performed in random order within 2 wk. The PET studies were performed after an overnight fast. All participants refrained from intake of caffeine-containing food or beverages for at least 18 h before the PET study. Each subject lay supine in the PET scanner. A catheter was inserted in the antecubital vein of each arm for the infusion of tracer, dipyridamole, perindoprilat, or placebo (saline). CPT was performed by lowering the subject's left foot and ankle into a tub filled with ice water. Thirty seconds later,  $^{13}\text{N}$ -ammonia was infused intravenously. The foot was kept for an additional 2 min in ice water to ensure that the stimulus lasted for the first 2 min of the dynamic image acquisition. Pharmacologic stress was induced by an intravenous dipyridamole infusion of 0.56 mg/kg over 4 min. Three minutes later,  $^{13}\text{N}$ -ammonia was infused. Perindoprilat, which in a pilot study had been "titrated" in 3 healthy volunteers to produce marked increases in the plasma concentrations of renin and angiotensin without causing hypotension, was infused as a bolus of 1.25 mg 15 min before the start of the scans, followed by a continuous infusion of 0.5 mg/h during the rest of the study.

Heart rate, blood pressure, and electrocardiography findings were monitored throughout the study.

### PET

**Image Acquisition.** The study was performed on a whole-body tomograph (Advance; General Electric Medical Systems, Milwaukee, WI) with 18 crystal rings forming 35 two-dimensional imaging planes spaced by 4.25 mm, and an intrinsic spatial resolution of 4–6 mm in full width at half maximum. The gantry width has a diameter of 55 cm, and the axial field of view is 15.2 cm. Two pin sources with  $^{68}\text{Ge}$  were used for the blank and transmission scan acquisitions. Corrections for dead time, attenuation, scatter, and decay were applied, and the images were reconstructed to an effective in-plane resolution of 7 mm in full width at half maximum using a Hanning filter.

Initially, a 2-min transmission scan was acquired for optimal positioning, which was then checked during the study by a cross-shaped low-power laser beam and pen markers on the skin. Movement was minimized by fastening a hook-and-loop strap across the subject's chest. The 3 image acquisitions, at rest, during CPT, and after dipyridamole, were performed in an identical matter separated by 50–60 min to allow for physical decay of  $^{13}\text{N}$ -ammonia activity. After a slow, intravenous bolus injection of 700 MBq  $^{13}\text{N}$ -ammonia over 30 s using an infusion pump (Harvard Apparatus, Inc., Holliston, MA), serial images were acquired for 20 min (24 frames:  $13 \times 6$  s,  $3 \times 12$  s,  $3 \times 20$  s,  $4 \times 30$  s, and  $1 \times 900$  s).

Because patient discomfort during CPT and the long scanning protocol increased the risk of motion artifacts, the 3 dynamic image acquisitions were interpolated by 2 transmission scans to ensure optimal correction for motion artifacts. Immediately after the dynamic acquisition sequence, a 5-min correction frame was applied, based on the assumption that the distribution of  $^{13}\text{N}$ -ammonia activity remained constant for the remaining 20–45 min. The 5-min frame was used to correct the residual  $^{13}\text{N}$ -ammonia and background activity of the subsequent transmission scan. Transmission data were acquired for 20 min. The first set of transmission data was subsequently used to generate attenuation correction factors for the baseline study. The second set of transmission data was used to generate attenuation correction factors for CPT and the dipyridamole study.

**Image Analysis.** For each frame of the serially acquired data, sets of 35 transaxial images were reconstructed. Each of these image datasets were resampled on a workstation (General Electric Medical Systems) into 12 contiguous short-axis cross-sections of the left ventricle.

For generation of time–activity curves, 6 serially acquired short-axis cross-sections (2 basal, 2 midventricular, and 2 apical) were selected for each subject, leaving out the 4 most apical and 2 most basal planes. Regions of interest (ROIs) were assigned to the last serial image (900 s) and copied to the first 16 serially acquired  $^{13}\text{N}$ -ammonia images (i.e., the initial 120 s of data after tracer injection) to obtain regional time–activity curves. Rectangular myocardial ROIs with an area of 64 mm<sup>2</sup> were placed to correspond to the anterior, lateral, and inferior walls of the left ventricle using a standardized template. The junction of the anterior right ventricular wall with the anterior interventricular septum was used to ensure a standardized anatomic location for the template. The septal ROI was omitted in our analysis to reduce the error introduced by dual spillover. These time–activity curves from 3 corresponding sectors in 6 planes were then averaged. A circular ROI with an area of approximately 50 mm<sup>2</sup> was situated over the center

**TABLE 1**  
Epidemiology of Study Groups

Characteristic	NIDDM patients	Control subjects	P
Number	10	10	
Age (y)	53 ± 8	60 ± 8	NS
Plasma glucose (fasting; mmol/L)	8.7 ± 1.8	5.2 ± 0.6	<0.01
Plasma hemoglobin A <sub>1c</sub> (%)	8.3 ± 1.7	5.1 ± 0.1	<0.01
Body mass index (kg/m <sup>2</sup> )	33 ± 6	26 ± 3	<0.05
Plasma cholesterol (mmol/L)	5.9 ± 1.2	5.6 ± 1.0	NS

NS = not statistically significant.  
Values are mean ± SD.

of the left ventricular blood pool to derive the arterial concentration curve used as an input function averaging the input time-activity curves from the 3 most basal planes. We corrected for partial-volume effects, with a recovery coefficient estimated from values obtained by echocardiographic measurement of the individual left ventricular free-wall thickness. The corrected time-activity curves were then fitted with a previously validated 2-compartment tracer kinetic model (8).

### Statistical Evaluation

Differences within groups were tested by paired *t* tests, and differences between groups were tested by unpaired *t* tests. *P* < 0.05 was considered significant.

## RESULTS

### CBF

During placebo infusion, resting CBF was similar in NIDDM patients and control subjects (Fig. 1A). CPT increased CBF by 20% in the control group (*P* < 0.05), whereas no increase was observed in the NIDDM group. After dipyridamole infusion, CBF increased 2- to 3-fold in NIDDM patients (*P* < 0.01) and 3- to 4-fold in control subjects (*P* < 0.01). The increase and the maximal CBF were significantly higher in control subjects than in patients (*P* < 0.05). During ACE-inhibitor infusion, resting CBF was similar in NIDDM patients and control subjects (Fig.

1B). CPT increased CBF by 14% in the NIDDM group (*P* < 0.05), whereas no increase was observed in the 5 subjects of the control group who received perindoprilat. After dipyridamole infusion, CBF increased 3- to 4-fold in both groups (*P* < 0.01). The increase and maximal CBFs in the patients were statistically not different from those in the 5 control subjects receiving perindoprilat or from those in the 10 control subjects during saline infusion. The individual flow responses to CPT are shown in Figure 2.


### Hemodynamics During CPT

CPT increased the rate-pressure product (RPP) approximately 30% in both the NIDDM group and the control group (Table 2; *P* < 0.01). Infusion of ACE inhibitor did not change the increase in RPP in response to CPT in any of the groups.


## DISCUSSION

In this study, we demonstrated with PET that maximal coronary flow is reduced in normotensive, normoalbuminuric NIDDM patients. This finding agrees with the findings of a previous study (9). The major factor connected with a reduction in CBF seems to be hyperglycemia (10). Concordant with this was our finding that NIDDM patients had significantly higher fasting glucose levels and hemoglobin A<sub>1c</sub> levels. Because none of the patients had signs of coronary artery disease (no symptoms; normal exercise electrocardiography findings), it is likely that the cause of abnormal flow regulation may, in part, be dysfunction of the endothelium. This idea is supported by the ability to induce endothelial dysfunction in healthy volunteers by hyperglycemia (11). The fact that infusion of an ACE inhibitor normalized the maximal CBF supports the absence of epicardial coronary artery disease in our patients. The beneficial effect of ACE inhibition on endothelial function in NIDDM has been described in a previous study (12). We used dipyridamole for the induction of maximal CBF. Does dipyridamole-induced maximal CBF reflect endothelial function? Although the direct effect of dipyridamole acting through adenosine is exerted on vascular smooth muscle and thus is not endothelium dependent, the subsequent increase in flow through shear stress has been found to lead to release of vasodilators from the endothelium. In concordance with this finding, a previous study showed that the coronary flow response to adenosine relates, in part, to endothelium-dependent vasodilatation (13). Furthermore, the mechanisms of adenosine-induced epicardial coronary artery dilatation also seem predominantly to be endothelium dependent (14). Taken together, the dipyridamole-induced CBF increase to a major part seems to reflect endothelial function in patients without structural coronary artery disease.

CPT is also regarded as a way of studying endothelial function, primarily based on comparison with the response to intracoronary infusion of acetylcholine. Through nociception, CPT activates the sympathetic nervous system and



**FIGURE 1.** CBF values at rest, during CPT, and after dipyridamole (DIPY) during saline infusion (A) or perindoprilat (ACE inhibitor) infusion (B). Values are mean  $\pm$  SEM for 10 subjects (5 for ACE inhibitor control subjects). \**P* < 0.05 vs. control subjects. #*P* < 0.05 vs. NIDDM patients. ##*P* < 0.01 vs. rest. White bars = NIDDM patients; black bars = control subjects.



**FIGURE 2.** Individual CBF responses to CPT in saline-treated (left panels) or perindoprilat-treated (right panels) NIDDM patients (top panels) or control subjects (bottom panels).

the release of catecholamines from the adrenal medulla to the blood. Although the catecholamines directly lead to vasoconstriction, the increased oxygen demand of the myocardium indirectly leads to a secondary increase in CBF in the normal heart. The net effect in the normal heart is vasodilatation and increased CBF. However, in patients with endothelial dysfunction, the loss of vasodilating mech-

anisms leads to insufficient or absence of vasodilation and increase in CBF. In our study, CPT increased CBF in most of the control subjects (7/10) but not in the NIDDM patients, although the hemodynamic responses were similar. This finding strongly suggests dysfunction of the endothelium in NIDDM. A concordant recent finding was that, when CPT was used in healthy volunteers and NIDDM

**TABLE 2**

Hemodynamics During Rest and Cold Pressor Test Performed With and Without ACE Inhibition with Perindoprilat

Parameter	Saline		Perindoprilat	
	NIDDM patients (n = 10)	Control subjects (n = 10)	NIDDM patients (n = 10)	Control subjects (n = 5)
Rest				
HR	65 ± 10	62 ± 12	64 ± 8	55 ± 4
SBP	123 ± 8	121 ± 10	127 ± 9	115 ± 14
HR × SBP	8,076 ± 1,344	7,558 ± 1,692	8,222 ± 1,213	6,352 ± 649*
Cold pressor test				
HR	74 ± 12	69 ± 14	74 ± 11	63 ± 8
SBP	144 ± 17	139 ± 12	148 ± 19	132 ± 13
HR × SBP	10,751 ± 2,174†	9,672 ± 2,275†	10,989 ± 2,287†	8,268 ± 888†‡
Change (%)				
HR × SBP	34 ± 21	28 ± 13	34 ± 23	30 ± 9

\*P < 0.01 vs. ACE-I + NIDDM.

†P < 0.01 vs. rest.

‡P < 0.05 vs. ACE-I + NIDDM.

HR = heart rate; SBP = systolic blood pressure.

Values are mean ± SD. Statistical comparisons for control group before and after perindoprilat was performed on paired observations on 5 subjects examined both before and after ACE inhibition.



patients with normal coronary angiograms, the flow increase in the left anterior descending coronary artery was significantly lower in the NIDDM patients although the increase in RPP was similar (15). The significant increase in CBF by CPT during ACE inhibition in the NIDDM group suggests improvement or normalization of endothelial function during ACE inhibition. The increase in CBF in response to CPT was not significant in the control group during ACE inhibition, but that is obviously explained by the low number of control subjects receiving perindoprilat. However, the findings regarding NIDDM patients are not weakened, because the same 10 patients were studied both during placebo and during ACE inhibition: With saline infusion, CBF increased in 4 NIDDM patients during CPT whereas CBF decreased in 6. During ACE inhibition, CBF increased in 8 of the 10 patients.

The increases in CBF during CPT are small even in control subjects, and CBF increased in only 7 of 10 subjects. CPT is therefore less useful for the study of endothelial function than would be dipyridamole, for example. In theory, this limitation could be circumvented by use of a stronger CPT. However, the test is also limited by the pain perceived by the subjects. A difference stemming from our use of foot immersion instead of hand immersion could also be argued. We find such a difference unlikely, since the increase in RPP in our study was similar or even higher than that found by others (15,16). Thus, the stimulus must have been quantitatively adequate. Furthermore, a study directly comparing different ways of performing CPT found equivalent cardiovascular responses using hand and foot immersion (17). Taking these factors together, we believe that foot CPT and hand CPT provide equivalent information on myocardial vasomotion.

## CONCLUSION

This study indicated that dipyridamole may be useful for the noninvasive examination of coronary endothelial dysfunction. In contrast, CPT seems less useful for this purpose because of the small and inconsistent CBF changes in response to the test.

## REFERENCES

1. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated

- non-insulin-dependent diabetes: role of dyslipidaemia. *Clin Sci (Lond)*. 1996;91:567-573.
2. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia*. 1992;35:771-776.
3. Williams SB, Cosco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol*. 1996;27:567-574.
4. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. *J Clin Invest*. 1996;97:2601-2610.
5. Zeiher AM, Drexler H, Wollschlaeger H, Saurbier B, Just H. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. *J Am Coll Cardiol*. 1989;14:1181-1190.
6. Beanlands RS, Muzik O, Melon P, et al. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography: determination of extent of altered vascular reactivity. *J Am Coll Cardiol*. 1995;26:1465-1475.
7. Gould KL, Schelbert HR, Phelps ME, Hoffman EJ. Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V. Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed tomography in intact dogs. *Am J Cardiol*. 1979;43:200-208.
8. Kuhle WG, Porenta G, Huang SC, et al. Quantification of regional myocardial blood flow using <sup>13</sup>N-ammonia and reoriented dynamic positron emission tomographic imaging. *Circulation*. 1992;86:1004-1017.
9. Yokoyama I, Momomura S, Ohtake T, Yonekura K, Nishikawa J, Sasaki Y, Omata M. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol*. 1997;30:1472-1477.
10. Yokoyama I, Ohtake T, Momomura S, et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. *Diabetes*. 1998;47:119-124.
11. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. *Circulation*. 1998;97:1695-1701.
12. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol*. 1999;33:1506-1511.
13. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. *Circulation*. 1995;92:2135-2141.
14. Lupi A, Buffon A, Finocchiaro ML, Conti E, Maseri A, Crea F. Mechanisms of adenosine-induced epicardial coronary artery dilatation. *Eur Heart J*. 1997;18:614-617.
15. Nitenberg A, Ledoux S, Valensi P, Sachs R, Attali JR, Antony I. Impairment of coronary microvascular dilation in response to cold pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. *Diabetes*. 2001;50:1180-1185.
16. Dubois-Rande JL, Dupouy P, Aptekar E, et al. Comparison of the effects of exercise and cold pressor test on the vasomotor response of normal and atherosclerotic coronary arteries and their relation to the flow-mediated mechanism. *Am J Cardiol*. 1995;76:467-473.
17. Saab PG, Llabre MM, Hurwitz BE, et al. The cold pressor test: vascular and myocardial response patterns and their stability. *Psychophysiology*. 1993;30:366-373.